Schonfeld Strategic Advisors LLC Clovis Oncology, Inc. Transaction History

Schonfeld Strategic Advisors LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$1.43 - $3.14 $14,729 - $32,342	-10,300 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$2.7 - $4.76 $27,810 - $49,028	10,300 New	10,300 $28,000
Q2 2021 Aug 16, 2021	SELL	$5.02 - $7.05 $129,551 - $181,939	-25,807 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$4.81 - $10.34 $124,131 - $266,844	25,807 New	25,807 $181,000
Q4 2020 Feb 16, 2021	SELL	$4.13 - $6.41 $1.11 Million - $1.72 Million	-267,646 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$4.82 - $7.72 $1.29 Million - $2.07 Million	267,646 New	267,646 $2,000
Q2 2020 Aug 14, 2020	SELL	$5.69 - $9.69 $82,988 - $141,328	-14,585 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$3.77 - $11.0 $54,985 - $160,435	14,585 New	14,585 $93,000
Q1 2018 May 15, 2018	SELL	$50.12 - $67.72 $3.47 Million - $4.69 Million	-69,240 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$57.69 - $84.58 $1.34 Million - $1.96 Million	23,176 Added 50.31%	69,240 $4.71 Million
Q3 2017 Nov 14, 2017	BUY	$67.17 - $84.81 $3.09 Million - $3.91 Million	46,064	46,064 $3.8 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.